Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue: +4.13%
EPS: −21.7%
Free cash flow: −63.7%

Quarter to September 2026, against a year earlier

561.51 4.21 −0.74%

Follow UTHR

Alert me

Market cap: $24.3B
P/E: 19.7×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

United Therapeutics Corporation 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 4, 2026 · accepted 6:30 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 29, 2025: 46 added · 36 removed · 63 modified; 3 with only figures updated; 10 moved without change

United Therapeutics Corporation 10-Q filed Nov 4, 2026

What changed

Stockrow Weekly